Neutralizing antibody responses in healthcare personnel after three doses of mRNA BNT162b2 vaccine and association with baseline characteristics and past SARS-CoV-2 infection

• Published in: Vaccine 2022-09, Vol.40 (40), p.5752-5756
• Main Authors: Psaridi, Loukia, Maltezou, Helena C., Simonidou, Sofia, Lialliou, Ioanna, Athanasopoulou, Despina, Haila, Zoi, Kyrimi, Areti, Giannopoulou, Ioanna, Giannousa, Styliani, Pseimada, Maria, Christofilea, Olympia, Dounias, George, Lanitis, Sophocles, Kremasmenou, Eirini
• Format: Article
• Language: English
• Subjects: Antibodies; Antibodies, Neutralizing; Antibodies, Viral; BNT162 Vaccine; Body mass index; Comorbidity; Coronaviruses; COVID-19; COVID-19 - prevention & control; COVID-19 vaccines; Delivery of Health Care; Disease transmission; Dosage; Drug dosages; Female; Flow cytometry; Health care; Healthcare personnel; Humans; Immunosuppressive agents; Infections; Laboratories; Medical personnel; mRNA; mRNA vaccine; mRNA Vaccines; Mutation; Neutralizing; Neutralizing antibodies; Personnel; RNA, Messenger; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Short Communication; Statistical analysis; Tobacco; Vaccines; Vaccines, Synthetic; Viral Vaccines
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2022.08.031

To estimate neutralizing antibody (NAb) immunity against SARS-CoV-2 in 739 healthcare personnel (HCP) vaccinated with three doses of BNT162b2 mRNA vaccine. Serum samples were collected at 3, 6, and 9 months after the second vaccine dose and at 7–55 days after the third dose. Samples were tested for NAbs against SARS-CoV-2 receptor binding domain. The mean inhibition rates at 3, 6, and 9 months after the second dose were 86.33%, 73.38%, and 61.18%, and increased to 95.57% after the booster dose. Younger HCP and HCP with past SARS-CoV-2 infection had higher inhibition rates while there was an inverse correlation between NAb levels and comorbidities or tobacco use (p-values